🚀 VC round data is live in beta, check it out!
ARS Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for ARS Pharmaceuticals and similar public comparables like Bicara Therapeutics, OPKO Health, Center Laboratories, MannKind and more.
ARS Pharmaceuticals Overview
About ARS Pharmaceuticals
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Founded
2016
HQ
Employees
160
Website
Sectors
Financials (LTM)
EV
$727M
ARS Pharmaceuticals Financials
ARS Pharmaceuticals reported last 12-month revenue of $101M.
In the same LTM period, ARS Pharmaceuticals generated $79M in gross profit and had net loss of ($167M).
Revenue (LTM)
ARS Pharmaceuticals P&L
In the most recent fiscal year, ARS Pharmaceuticals reported revenue of $84M and EBITDA of ($169M).
ARS Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $101M | XXX | $84M | XXX | XXX | XXX |
| Gross Profit | $79M | XXX | $64M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($169M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (200%) | XXX | XXX | XXX |
| EBIT Margin | (170%) | XXX | (213%) | XXX | XXX | XXX |
| Net Profit | ($167M) | XXX | ($171M) | XXX | XXX | XXX |
| Net Margin | (164%) | XXX | (203%) | XXX | XXX | XXX |
| Net Debt | — | — | $55M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ARS Pharmaceuticals Stock Performance
ARS Pharmaceuticals has current market cap of $917M, and enterprise value of $727M.
Market Cap Evolution
ARS Pharmaceuticals' stock price is $9.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $727M | $917M | 0.0% | XXX | XXX | XXX | $-1.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialARS Pharmaceuticals Valuation Multiples
ARS Pharmaceuticals trades at 7.2x EV/Revenue multiple, and (4.3x) EV/EBITDA.
EV / Revenue (LTM)
ARS Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, ARS Pharmaceuticals has market cap of $917M and EV of $727M.
Equity research analysts estimate ARS Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ARS Pharmaceuticals has a P/E ratio of (5.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $917M | XXX | $917M | XXX | XXX | XXX |
| EV (current) | $727M | XXX | $727M | XXX | XXX | XXX |
| EV/Revenue | 7.2x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.3x) | XXX | XXX | XXX |
| EV/EBIT | (4.2x) | XXX | (4.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | 11.4x | XXX | XXX | XXX |
| P/E | (5.5x) | XXX | (5.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ARS Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ARS Pharmaceuticals Margins & Growth Rates
ARS Pharmaceuticals' revenue in the last 12 month grew by 89%.
ARS Pharmaceuticals' revenue per employee in the last FY averaged $0.6M.
ARS Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 89% | XXX | 94% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (200%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5375% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 289% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ARS Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bicara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Center Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| MannKind | XXX | XXX | XXX | XXX | XXX | XXX |
| Arbutus Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ARS Pharmaceuticals M&A Activity
ARS Pharmaceuticals acquired XXX companies to date.
Last acquisition by ARS Pharmaceuticals was on XXXXXXXX, XXXXX. ARS Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ARS Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialARS Pharmaceuticals Investment Activity
ARS Pharmaceuticals invested in XXX companies to date.
ARS Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. ARS Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ARS Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ARS Pharmaceuticals
| When was ARS Pharmaceuticals founded? | ARS Pharmaceuticals was founded in 2016. |
| Where is ARS Pharmaceuticals headquartered? | ARS Pharmaceuticals is headquartered in United States. |
| How many employees does ARS Pharmaceuticals have? | As of today, ARS Pharmaceuticals has over 160 employees. |
| Who is the CEO of ARS Pharmaceuticals? | ARS Pharmaceuticals' CEO is Richard E. Lowenthal. |
| Is ARS Pharmaceuticals publicly listed? | Yes, ARS Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of ARS Pharmaceuticals? | ARS Pharmaceuticals trades under SPRY ticker. |
| When did ARS Pharmaceuticals go public? | ARS Pharmaceuticals went public in 2022. |
| Who are competitors of ARS Pharmaceuticals? | ARS Pharmaceuticals main competitors are Bicara Therapeutics, OPKO Health, Center Laboratories, MannKind. |
| What is the current market cap of ARS Pharmaceuticals? | ARS Pharmaceuticals' current market cap is $917M. |
| What is the current revenue of ARS Pharmaceuticals? | ARS Pharmaceuticals' last 12 months revenue is $101M. |
| What is the current revenue growth of ARS Pharmaceuticals? | ARS Pharmaceuticals revenue growth (NTM/LTM) is 89%. |
| What is the current EV/Revenue multiple of ARS Pharmaceuticals? | Current revenue multiple of ARS Pharmaceuticals is 7.2x. |
| Is ARS Pharmaceuticals profitable? | No, ARS Pharmaceuticals is not profitable. |
| What is the current net income of ARS Pharmaceuticals? | ARS Pharmaceuticals' last 12 months net income is ($167M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.